Treatment of unresectable and resectable stage IV colorectal cancer.

IF 1.1 Q4 ONCOLOGY
Julia L Bachler, Gazala N Khan, Ira S Wollner, Philip A Philip
{"title":"Treatment of unresectable and resectable stage IV colorectal cancer.","authors":"Julia L Bachler, Gazala N Khan, Ira S Wollner, Philip A Philip","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer is the third most commonly diagnosed cancer in the United States. Approximately 20% of patients have metastatic disease at diagnosis, and a proportion of patients with initially localized disease will experience systemic disease recurrence. In the era of molecular subtyping, we have an increasing number of systemic therapies and the opportunity to individualize the treatment of patients with advanced disease. Nonetheless, the 5-year overall survival rate remains unsatisfactory for this patient population. Most patients will be treated with palliative cytotoxic therapy, often with an added monoclonal antibody. Molecular subtyping allows patients to receive targeted therapies upon further lines of therapy. A small portion of patients will have oligometastases that may be amenable to resection or locoregional therapies to help improve outcomes with systemic therapy. Here, we review the current treatment of patients with unresectable and resectable stage IV colorectal cancer, with a focus on pharmacologic therapies.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Advances in Hematology & Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer is the third most commonly diagnosed cancer in the United States. Approximately 20% of patients have metastatic disease at diagnosis, and a proportion of patients with initially localized disease will experience systemic disease recurrence. In the era of molecular subtyping, we have an increasing number of systemic therapies and the opportunity to individualize the treatment of patients with advanced disease. Nonetheless, the 5-year overall survival rate remains unsatisfactory for this patient population. Most patients will be treated with palliative cytotoxic therapy, often with an added monoclonal antibody. Molecular subtyping allows patients to receive targeted therapies upon further lines of therapy. A small portion of patients will have oligometastases that may be amenable to resection or locoregional therapies to help improve outcomes with systemic therapy. Here, we review the current treatment of patients with unresectable and resectable stage IV colorectal cancer, with a focus on pharmacologic therapies.

治疗无法切除和可切除的 IV 期结直肠癌。
结直肠癌是美国第三大常见癌症。约有 20% 的患者在确诊时已患有转移性疾病,而一部分最初患有局部疾病的患者会出现全身性疾病复发。在分子亚型时代,我们拥有越来越多的系统疗法,并有机会对晚期患者进行个体化治疗。尽管如此,这一患者群体的 5 年总生存率仍不能令人满意。大多数患者将接受姑息性细胞毒治疗,通常还需要添加单克隆抗体。通过分子亚型分析,患者可以在进一步治疗后接受靶向治疗。一小部分患者会出现寡转移灶,可进行切除或局部治疗,以帮助改善全身治疗的疗效。在此,我们回顾了目前对无法切除和可切除的 IV 期结直肠癌患者的治疗方法,重点是药物疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
99
期刊介绍: Clinical Advances in Hematology & Oncology (CAH&O) is a monthly peer-reviewed journal reaching more than 27,000 hematology and oncology clinicians. CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of today’s top thought leaders in hematology & oncology, including feature-length review articles, monthly columns consisting of engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development, and clinical case studies with expert commentary. CAH&O also publishes industry-supported meeting highlights, clinical roundtable monographs, and clinical review supplements.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信